Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma

SIMPLE SUMMARY: In this manuscript, we reported that a newly developed recombinant human IL15 fused with albumin binding domain (hIL15-ABD) showed superior biological half-life, pharmacokinetic and anti-tumor immunity than wild-type (WT) hIL15. Our hIL-15-ABD can effectively enhance anti-tumor effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Fei-Ting, Liu, Yu-Chang, Tsai, Chang-Liang, Yueh, Po-Fu, Chang, Chih-Hsien, Lan, Keng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070266/
https://www.ncbi.nlm.nih.gov/pubmed/33918641
http://dx.doi.org/10.3390/cancers13081789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070266/
https://www.ncbi.nlm.nih.gov/pubmed/33918641
http://dx.doi.org/10.3390/cancers13081789

Ejemplares similares